NASDAQ:TWST Twist Bioscience (TWST) Stock Price, News & Analysis $60.57 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$60.54 -0.02 (-0.04%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Twist Bioscience Stock (NASDAQ:TWST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Twist Bioscience alerts:Sign Up Key Stats Today's Range$56.38▼$61.9550-Day Range$42.07▼$63.2052-Week Range$23.30▼$66.06Volume1.62 million shsAverage Volume1.47 million shsMarket Capitalization$3.77 billionP/E RatioN/ADividend YieldN/APrice Target$58.00Consensus RatingModerate Buy Company Overview Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods. At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides. These products support applications across research, drug discovery, diagnostic development, and synthetic biology. By combining microfluidics, proprietary software, and chip-based synthesis, the company claims enhanced accuracy and uniformity while driving down per-base costs. Twist also offers next-generation sequencing services and bioinformatics support to accelerate customer workflows. Twist Bioscience serves a global customer base spanning pharmaceutical and biotechnology companies, academic and government research institutions, agricultural and industrial biotechnology firms, and emerging data-storage ventures exploring DNA as a long-term archival medium. In addition to its primary manufacturing facility in California, the company has expanded operations to Europe, enabling faster delivery and localized support in key markets. Leadership at Twist is anchored by co-founder and Chief Executive Officer Dr. Emily Leproust, whose background in chemistry and experience at leading genomics organizations helped shape the company’s technology strategy. Under her guidance, Twist has grown from a single R&D lab to a public company focused on scaling DNA synthesis for a wide range of commercial applications.AI Generated. May Contain Errors. Read More Twist Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreTWST MarketRank™: Twist Bioscience scored higher than 35% of companies evaluated by MarketBeat, and ranked 706th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingTwist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Twist Bioscience is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTwist Bioscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Twist Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Twist Bioscience are expected to grow in the coming year, from ($1.86) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Twist Bioscience is -45.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Twist Bioscience is -45.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTwist Bioscience has a P/B Ratio of 8.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Twist Bioscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.06% of the float of Twist Bioscience has been sold short.Short Interest Ratio / Days to CoverTwist Bioscience has a short interest ratio ("days to cover") of 10.46, which indicates bearish sentiment.Change versus previous monthShort interest in Twist Bioscience has recently decreased by 4.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTwist Bioscience does not currently pay a dividend.Dividend GrowthTwist Bioscience does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.95 News SentimentTwist Bioscience has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Twist Bioscience this week, compared to 4 articles on an average week.Search Interest4 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,566,533.00 in company stock.Percentage Held by Insiders3.08% of the stock of Twist Bioscience is held by insiders.Percentage Held by InstitutionsTwist Bioscience has minimal institutional ownership at this time.Read more about Twist Bioscience's insider trading history. Receive TWST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TWST Stock News HeadlinesTwist Bioscience Corporation (TWST) Expands its Clonal Gene Offering to Include Long and Complex SequencesMay 23 at 2:31 AM | insidermonkey.comTwist Bioscience Corporation (TWST) Analyst/Investor Day - SlideshowMay 22 at 2:34 PM | seekingalpha.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 25 at 1:00 AM | Brownstone Research (Ad)Insider Selling: Twist Bioscience (NASDAQ:TWST) Director Sells 12,000 Shares of StockMay 15, 2026 | insidertrades.comTwist Bioscience (TWST) price target increased by 20.55% to 64.90May 15, 2026 | msn.comCathie Wood trims $3.17 M of surging Twist Bioscience stockMay 14, 2026 | msn.comCathie Wood’s ARK sells Twist Bioscience stock, buys Intellia sharesMay 12, 2026 | investing.comTwist Bioscience (NASDAQ:TWST) Director Melissa Starovasnik Sells 500 SharesApril 30, 2026 | insidertrades.comSee More Headlines TWST Stock Analysis - Frequently Asked Questions How have TWST shares performed this year? Twist Bioscience's stock was trading at $31.72 on January 1st, 2026. Since then, TWST stock has increased by 91.0% and is now trading at $60.57. How were Twist Bioscience's earnings last quarter? Twist Bioscience Corporation (NASDAQ:TWST) issued its earnings results on Monday, May, 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.22. The company's quarterly revenue was up 19.3% on a year-over-year basis. Read the conference call transcript. When did Twist Bioscience IPO? Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers. Who are Twist Bioscience's major shareholders? Top institutional investors of Twist Bioscience include EdgePoint Investment Group Inc. (8.64%), Sumitomo Mitsui Trust Group Inc. (2.44%), Amova Asset Management Americas Inc. (2.40%) and First Light Asset Management LLC (1.41%). Insiders that own company stock include Emily M Leproust, William Banyai, Patrick John Finn, Dennis Cho, Paula Green, Adam Laponis, Robert F Werner, Melissa A Starovasnik, Robert Chess and Jan Johannessen. View institutional ownership trends. How do I buy shares of Twist Bioscience? Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Twist Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Twist Bioscience investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/04/2026Today5/25/2026Next Earnings (Estimated)8/03/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TWST's financial health is in the Green zone, according to TradeSmith. TWST has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TWST CIK1581280 Webwww.twistbioscience.com Phone(800) 719-0671FaxN/AEmployees990Year Founded2013Price Target and Rating Average Price Target for Twist Bioscience$58.00 High Price Target$80.00 Low Price Target$41.00 Potential Upside/Downside-4.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.67 million Net Margins-19.85% Pretax Margin-19.67% Return on Equity-26.73% Return on Assets-19.15% Debt Debt-to-Equity Ratio0.03 Current Ratio2.70 Quick Ratio2.42 Sales & Book Value Annual Sales$376.57 million Price / Sales10.02 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book8.29Miscellaneous Outstanding Shares62,270,000Free Float60,353,000Market Cap$3.77 billion OptionableOptionable Beta2.22 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TWST) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Twist Bioscience Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Twist Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
